Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice

被引：0
|
作者：
Krekeler, G. [1 ]
Neuhof, A. [1 ]
Dreyling, M. [2 ]
Hess, G. [3 ]
Kalanovic, D. [1 ]
机构：
[1] Pfizer Pharma GmbH, Berlin, Germany
[2] Univ Munich, Munich, Germany
[3] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
来源：
Oncology Research and Treatment | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P226
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [31] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [32] Efficacy and safety of zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a systematic review
    Santoso, A. Febrian
    Margouw, R. Relia
    Maulidia, S. Azrianindita
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1341 - S1341
  • [33] Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma
    Jurczak, Wojciech
    Ramanathan, Sundra
    Giri, Pratyush
    Romano, Alessandra
    Mocikova, Heidi
    Clancy, Jill
    Lechuga, Mariajose
    Casey, Michelle
    Boni, Joseph
    Giza, Agnieszka
    Hess, Georg
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 670 - 678
  • [34] Radioimmunotherapy (RIT) of relapsed or refractory mantle cell lymphoma (MCL)
    Elstrom, R
    Chong, E
    Andreadis, C
    Shrikanthan, S
    Downs, L
    Fellin, E
    Tsai, D
    Nasta, S
    Svoboda, J
    Maffi, J
    Alavi, A
    Schuster, S
    ANNALS OF ONCOLOGY, 2005, 16 : 170 - 170
  • [35] Evaluation of safety, tolerability and activity of Temsirolimus in patients with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Krekeler, G.
    Woike, M.
    Bergmann, L.
    Roigas, J.
    Steiner, T.
    Kalanovic, D.
    ONKOLOGIE, 2013, 36 : 77 - 77
  • [36] Evaluation of safety, tolerability and activity of temsirolimus in patients with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Kalanovic, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S667 - S667
  • [37] Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma.
    Bair, A.
    Hess, G.
    Boni, J.
    Offner, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY
    Hess, G.
    Romaguera, J.
    Herbrecht, R.
    Verhoef, G.
    Crump, M.
    Hanushevsky, O.
    Strahs, A.
    Hewes, B.
    Berkenblit, A.
    Coiffier, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 391 - 392
  • [39] TEMSIROLIMUS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: DOES PROGNOSTIC RISK AFFECT OUTCOMES?
    Hess, G.
    Kang, L.
    Moran, P.
    HAEMATOLOGICA, 2012, 97 : 101 - 101
  • [40] Evaluation of safety, tolerability and activity of Temsirolimus in patients (pts) with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Goebell, P. J.
    Goehler, T.
    Harich, H. -D
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 88 - 88
12345